Evolving Breast Cancer Treatments 2025: Personalized Approaches Enhance Treatment

HER2-Positive Breast Cancer: Targeted Therapies and Immunotherapy

HER2-positive breast cancer is characterized by the overexpression of the HER2 protein, which promotes the rapid growth of cancer cells. This subtype can be addressed with targeted therapies that aim to inhibit the HER2 receptors on cancer cells, thus potentially slowing their proliferation. Here are some available therapies:

1. Trastuzumab (Herceptin): Trastuzumab targets HER2 receptors, either alone or with chemotherapy (Source 1). Typically administered intravenously, it plays a role in both early-stage and metastatic cancers.

2. Pertuzumab (Perjeta): Often used with trastuzumab and chemotherapy, pertuzumab offers an additional level of HER2 activity inhibition, contributing to a more comprehensive treatment strategy for advanced HER2-positive cancers (Source 2).

3. Ado-trastuzumab Emtansine (Kadcyla) and Fam-trastuzumab Deruxtecan (Enhertu): These are antibody-drug conjugates designed to deliver cytotoxic agents directly to cancer cells, aiming to reduce damage to normal cells. They are used in cases where standard HER2 therapies have been inadequate (Source 2).

4. HER2-Low Targeting: Fam-trastuzumab deruxtecan (Enhertu) now also addresses HER2-low metastatic breast cancer, focusing on tumors with low HER2 expression (Source 1). This introduces more targeted treatment options for patients who were previously considered HER2-negative.

Hormone Receptor-Positive (HR+) Breast Cancer: Hormonal Therapies and Combinations

For HR-positive breast cancers, which are influenced by hormones such as estrogen and progesterone, hormonal therapies are central to treatment, often combined with newer targeted agents:

1. CDK4/6 Inhibitors: Medications like palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) are important for managing HR-positive, HER2-negative breast cancer. These inhibitors aim to block proteins that promote cancer cell division, typically used alongside endocrine therapy to enhance hormonal treatment (Source 3).

2. Selective Estrogen Receptor Degraders (SERDs): New agents like elacestrant can be utilized alone or with CDK4/6 inhibitors, designed to degrade estrogen receptors on cancer cells to potentially impede tumor growth (Source 3).

3. Everolimus (Afinitor): When used with hormonal therapies in advanced settings, everolimus aims to overcome resistance by targeting mTOR protein pathways involved in cell proliferation (Source 2).

4. Emerging Combinations: Research such as PALMARES-2 (Source 3) investigates combinations like abemaciclib with other agents to potentially extend progression-free survival in HR-positive settings. The studies reveal different efficiencies based on the type of CDK inhibitors used, contributing to insights for tailored treatments.

Management of Metastatic Breast Cancer

Addressing metastatic breast cancer, whether HER2-positive or HR-positive, often involves an integrated treatment approach:

• Immunotherapy: While standard immunotherapies are evolving for HER2-positive breast cancer, some targeted therapies with monoclonal antibodies may support the body’s immune response to cancer cells (Source 2).

• Biomarker-Driven Decisions: Testing for biomarkers remains crucial, as HER2 and hormone receptor statuses can change. Ongoing testing permits adaptations in treatment strategies, aiding in the selection of effective therapies (Source 3).

• Antibody-Drug Conjugates (ADCs): Novel ADCs such as sacituzumab govitecan (Trodelvy) hold promise in advanced cases, especially when other treatments are not successful. These ADCs aim to deliver chemotherapy directly to cancer cells and represent promising developments in HR-positive cases (Source 2).

Considerations for Patient Care

1. Cardiotoxicity Monitoring: As some HER2-targeted therapies may lead to cardiotoxicity, regular cardiac screenings like echocardiograms are recommended. This monitoring is vital for managing potential side effects while continuing effective treatment (Source 1).

2. Cost and Accessibility: The financial impact of these therapies can be significant. It is advisable for patients to discuss costs with healthcare providers, who can offer guidance on insurance coverage and financial resources.

3. Survivorship Care: Post-treatment, developing a survivorship care plan, incorporating health monitoring, lifestyle advice, and psychological support, is essential for long-term patient well-being (Source 1).

In 2025, patients with HER2-positive and HR-positive breast cancer have more options than ever before. Integrating targeted therapies, innovative hormonal treatments, and the potential of immunotherapy creates a comprehensive toolkit for oncologists, facilitating personalized cancer treatment strategies tailored to each patient’s unique situation.

Sources:

1. Living Beyond Breast Cancer: HER2-Positive Breast Cancer
2. American Cancer Society: Targeted Therapy for Breast Cancer
3. OncLive: HR+ HER2- Breast Cancer Treatments

Disclaimer: All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. The information and materials contained in these pages and the terms, conditions and descriptions that appear, are subject to change without notice.